Physicians' Academy for Cardiovascular Education

Inflammation & cardiovascular disease: Exploring new options for intervention

ESC Amsterdam, September 2, 2012

Oct. 4, 2013


The symposium Inflammation & cardiovascular disease: Exploring new options for intervention ​was held at the congress of the European society of Cardiology (ESC) in Amsterdam on September 2, 2013.


Educational objectives

  • Review the current evidence supporting the inflammatory hypotheses of atherothrombosis
  • Review the epidemiology of hsCRP in risk stratification in CV disease
  • Discuss the rationale for lowering vascular events by inhibition of inflammation
  • Discuss the mechanism of blocking the pro-inflammatory cytokine interleukin-1β (IL-1β) with a monoclonal antihuman antibody
  • Discuss the potential of current and future strategies targeting inflammation in cardiovascular disease
  • Outline current ongoing clinical development programs aimed to address the inflammation hypothesis in cardiovascular disease


 

Inflammation biology in atherosclerosis

Peter Libby, MD
Mallinckrodt Professor of Medicine at Harvard Medical School,
Chief of the Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA
 

Start videopresentation

 


 

 


 

Biomarkers of inflammation and atherosclerotic risk

Wolfgang Koenig, MD
Professor of Medicine/Cardiology at University of Ulm Medical School, Ulm, Germany
 

Start videopresentation

 


 

 

 

Targeting inflammation in prevention of atherosclerotic events

Paul M Ridker, MD,
Eugene Braunwald Professor of Medicine at Harvard Medical School,
Director, Center for Cardiovascular Disease Prevention, Divisions of Cardiovascular Diseases and Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts. USA
Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
 

Start videopresentation

 


 

This  EBAC accredited symposium held during ESC 2013 was supported by an unrestricted educational grant from Novartis Pharma AG
 

Share this page with your colleagues and friends: